Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways Plc (Nasdaq: CMPS) is advancing innovative mental health solutions through its COMP360 psilocybin therapy program. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.
Investors and researchers will find timely updates on regulatory progress, including FDA Breakthrough Therapy designations and international clinical trials. All content is curated to support informed analysis of the company's progress in treatment-resistant depression and related mental health conditions.
Key focus areas include therapy development milestones, healthcare collaboration models, and intellectual property advancements. Resources are organized to help track the company's evidence-based approach to psychedelic-assisted therapies within rigorous clinical frameworks.
Bookmark this page for direct access to primary source materials about CMPS's work in mental health innovation. Visit regularly to stay current with developments in this pioneering sector of biotechnology.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit. The company's management team will engage in a fireside chat on September 26, 2024, at 1:20pm ET.
This event highlights Compass Pathways' involvement in the growing field of psychedelic-based therapies and novel approaches to neuropsychiatry. Interested parties can access a live audio webcast of the chat through the Events page on the Compass website. The recording will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.
Compass Pathways (NASDAQ: CMPS) reported its Q2 2024 financial results and business highlights. Key points include:
1. Top-line data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in Q4 2024.
2. Gino Santini to join as Board Chairman; Lori Englebert named new Chief Commercial Officer.
3. Cash position of $228.6 million, expected to fund operations into 2026.
4. Q2 2024 net loss of $38.1 million ($0.56 per share), compared to $28.3 million ($0.62 per share) in Q2 2023.
5. Positive results from phase 2 post-traumatic stress disorder study.
6. Q3 2024 net cash used in operating activities expected to be $32-38 million; full-year 2024 expected to be $110-130 million.
Compass Pathways has appointed Lori Englebert as Chief Commercial Officer, effective July 8, 2024. Lori joins from Axsome Therapeutics, where she was instrumental in the company's transition from clinical to commercial stage. Her experience includes commercializing CNS-focused assets at Axsome and Amgen. This appointment follows Teri Loxam as CFO and Dr. Michael Gold as Chief R&D Officer earlier this year. CEO Kabir Nath highlights the strengthened leadership team as important for navigating phase 3 trials and potential regulatory approval of COMP360, a psilocybin treatment for treatment-resistant depression.
Compass Pathways plc announced its first quarter 2024 financial results and key business highlights, including positive phase 2 COMP360 data in PTSD, on track phase 3 pivotal program in TRD, new commercial collaborations, appointment of Michael Gold as Head of R&D, and financial updates. The company's cash position was $262.9 million as of March 31, 2024.
Compass Pathways plc (Nasdaq: CMPS) reported top-line results from an open-label phase 2 study evaluating the safety and tolerability of COMP360 psilocybin treatment in 22 patients with PTSD. The study showed durable improvement in symptoms, with a significant reduction in the mean CAPS-5 total score and Sheehan Disability Scale (SDS) score. The administration of COMP360 was well-tolerated, with high response and remission rates observed. The results suggest a potential clinically meaningful benefit for patients with PTSD and open up possibilities for further research.
Compass Pathways plc (CMPS) partners with Mindful Health Solutions (MHS) to develop a cost-effective delivery model for COMP360 psilocybin treatment for treatment-resistant depression. This collaboration aims to understand potential approaches to deliver COMP360 in different care settings. MHS, a top behavioral health care provider in the US, will work with Compass to research patient pathways, therapist training needs, treatment rooms, and reimbursement considerations for psychedelic treatments. The goal is to make innovative treatments accessible to patients living with depression.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
